By Fineline Cube 
China-based Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the signing of three distribution and supply agreements with Thailand’s Interpharma Public Company Limited. The agreements cover NVK002, a topical ophthalmic atropine solution for pediatric myopia progression; Brimochol PF, a presbyopia treatment; and six generic glaucoma medications, including bimatoprost, bimatoprost timolol, latanoprost, latanoprost timolol, travoprost, and travoprost timolol.
Product Portfolio and Terms
Under the terms of the agreements, Interpharma has secured exclusive rights to import, distribute, promote, market, and sell these products in Thailand. This includes responsibility for local regulatory filings. In return, Zhaoke will receive non-refundable, non-deductible advance payments and additional milestone payments tied to specific commercial achievements.
Market Expansion and Impact
This strategic partnership marks a significant step in Zhaoke’s international expansion, particularly in the Southeast Asian market. By leveraging Interpharma’s local expertise, Zhaoke aims to enhance market penetration and provide Thai patients with access to innovative ophthalmic treatments.-Fineline Info & Tech